Related Experiment Video
Updated: Jun 28, 2026
07:09
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Hypercoagulability in sickle cell disease and beta-thalassemia
Sylvia T Singer1, Kenneth I Ataga
1Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA.
Current Molecular Medicine
|November 11, 2008
Summary
Sickle cell disease (SCD) and beta-thalassemia patients show increased clotting risks due to complex factors. Further research is needed to explore anticoagulant therapies for these inherited blood disorders.
Area of Science:
- Hematology
- Vascular Biology
- Genetics
Background:
- Sickle cell disease (SCD) and beta-thalassemia are common inherited blood disorders with distinct mechanisms.
- Both conditions share a prothrombotic state characterized by heightened platelet and coagulation activation.
- Patients with SCD and beta-thalassemia often present with reduced levels of natural anticoagulant proteins.
Purpose of the Study:
- To investigate the shared hypercoagulable state in sickle cell disease (SCD) and beta-thalassemia.
- To explore the multifactorial pathogenesis contributing to thrombotic complications in these hemoglobinopathies.
- To highlight the need for further research into hemostatic activation and potential therapeutic interventions.
Main Methods:
- This study reviews existing literature on the pathophysiology of SCD and beta-thalassemia, focusing on hemostatic abnormalities.
- Analysis of factors contributing to hypercoagulability, including red blood cell membrane changes, ischemia-reperfusion injury, and nitric oxide depletion.
- Examination of the role of decreased anticoagulant proteins in disease progression.
Main Results:
- Patients with SCD and beta-thalassemia exhibit significantly increased platelet and coagulation activation.
- Reduced levels of natural anticoagulant proteins are a common feature in both diseases.
- Thrombotic complications in these conditions may stem from a shared underlying hypercoagulable pathogenesis.
Conclusions:
- The hypercoagulability in SCD and beta-thalassemia is multifactorial, involving RBC abnormalities, ischemia-reperfusion, and nitric oxide depletion.
- Hemostatic activation plays a crucial role in the pathophysiology of these inherited blood disorders.
- Controlled studies with anticoagulants and antiplatelet agents are essential to clarify the role of hypercoagulability in specific complications and guide treatment strategies.
Related Concept Videos
01:49Multiple Allele Traits
The Concept of Multiple Allelism
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...